Articles tagged with Cancer Medication
Comprehensive exploration of living organisms, biological systems, and life processes across all scales from molecules to ecosystems. Encompasses cutting-edge research in biology, genetics, molecular biology, ecology, biochemistry, microbiology, botany, zoology, evolutionary biology, genomics, and biotechnology. Investigates cellular mechanisms, organism development, genetic inheritance, biodiversity conservation, metabolic processes, protein synthesis, DNA sequencing, CRISPR gene editing, stem cell research, and the fundamental principles governing all forms of life on Earth.
Comprehensive medical research, clinical studies, and healthcare sciences focused on disease prevention, diagnosis, and treatment. Encompasses clinical medicine, public health, pharmacology, epidemiology, medical specialties, disease mechanisms, therapeutic interventions, healthcare innovation, precision medicine, telemedicine, medical devices, drug development, clinical trials, patient care, mental health, nutrition science, health policy, and the application of medical science to improve human health, wellbeing, and quality of life across diverse populations.
Comprehensive investigation of human society, behavior, relationships, and social structures through systematic research and analysis. Encompasses psychology, sociology, anthropology, economics, political science, linguistics, education, demography, communications, and social research methodologies. Examines human cognition, social interactions, cultural phenomena, economic systems, political institutions, language and communication, educational processes, population dynamics, and the complex social, cultural, economic, and political forces shaping human societies, communities, and civilizations throughout history and across the contemporary world.
Fundamental study of the non-living natural world, matter, energy, and physical phenomena governing the universe. Encompasses physics, chemistry, earth sciences, atmospheric sciences, oceanography, materials science, and the investigation of physical laws, chemical reactions, geological processes, climate systems, and planetary dynamics. Explores everything from subatomic particles and quantum mechanics to planetary systems and cosmic phenomena, including energy transformations, molecular interactions, elemental properties, weather patterns, tectonic activity, and the fundamental forces and principles underlying the physical nature of reality.
Practical application of scientific knowledge and engineering principles to solve real-world problems and develop innovative technologies. Encompasses all engineering disciplines, technology development, computer science, artificial intelligence, environmental sciences, agriculture, materials applications, energy systems, and industrial innovation. Bridges theoretical research with tangible solutions for infrastructure, manufacturing, computing, communications, transportation, construction, sustainable development, and emerging technologies that advance human capabilities, improve quality of life, and address societal challenges through scientific innovation and technological progress.
Study of the practice, culture, infrastructure, and social dimensions of science itself. Addresses how science is conducted, organized, communicated, and integrated into society. Encompasses research funding mechanisms, scientific publishing systems, peer review processes, academic ethics, science policy, research institutions, scientific collaboration networks, science education, career development, research programs, scientific methods, science communication, and the sociology of scientific discovery. Examines the human, institutional, and cultural aspects of scientific enterprise, knowledge production, and the translation of research into societal benefit.
Comprehensive study of the universe beyond Earth, encompassing celestial objects, cosmic phenomena, and space exploration. Includes astronomy, astrophysics, planetary science, cosmology, space physics, astrobiology, and space technology. Investigates stars, galaxies, planets, moons, asteroids, comets, black holes, nebulae, exoplanets, dark matter, dark energy, cosmic microwave background, stellar evolution, planetary formation, space weather, solar system dynamics, the search for extraterrestrial life, and humanity's efforts to explore, understand, and unlock the mysteries of the cosmos through observation, theory, and space missions.
Comprehensive examination of tools, techniques, methodologies, and approaches used across scientific disciplines to conduct research, collect data, and analyze results. Encompasses experimental procedures, analytical methods, measurement techniques, instrumentation, imaging technologies, spectroscopic methods, laboratory protocols, observational studies, statistical analysis, computational methods, data visualization, quality control, and methodological innovations. Addresses the practical techniques and theoretical frameworks enabling scientists to investigate phenomena, test hypotheses, gather evidence, ensure reproducibility, and generate reliable knowledge through systematic, rigorous investigation across all areas of scientific inquiry.
Study of abstract structures, patterns, quantities, relationships, and logical reasoning through pure and applied mathematical disciplines. Encompasses algebra, calculus, geometry, topology, number theory, analysis, discrete mathematics, mathematical logic, set theory, probability, statistics, and computational mathematics. Investigates mathematical structures, theorems, proofs, algorithms, functions, equations, and the rigorous logical frameworks underlying quantitative reasoning. Provides the foundational language and tools for all scientific fields, enabling precise description of natural phenomena, modeling of complex systems, and the development of technologies across physics, engineering, computer science, economics, and all quantitative sciences.
Researchers found that oral drug ZD1839 suppressed the growth of ER-negative breast cancer cells and delayed the formation of tumors in transgenic mice. The treatment also reduced proliferation of normal breast cells by 20.3% and tumor cells by 42%. However, long-term safety data are needed for further research.
The Penn State project aims to create interactive maps of cancer rates in specific geographic areas, enabling better planning and evaluation of cancer interventions. Based on prostate and colorectal cancers, the model can be expanded to other states, utilizing available screenings and interventions to reduce cancer burden.
The study aims to identify new forms of therapy and hope for those at high risk of developing cancer. Six institutions will design and conduct experiments to test the cancer prevention potential of substances affecting various processes involved in cancer's formation and spread.
The American Society of Hematology has awarded Gary Gilliland and Janet Rowley for their significant contributions to hematology research. Dr. Gilliland's work on the molecular pathogenesis of leukemia and discovery of a cause for hypereosinophilic syndrome have provided new ways to understand cancer, while Dr. Rowley's discoveries of ...
A phase II trial found that AMD-3100, a new drug, increases the availability of stem cells in cancer patients undergoing transplantation. This boosts the chances of successful transplantation and may reduce the number of collections needed.
A new study found that three months is too soon to judge a patient's response to Gleevec, a common CML treatment. Researchers discovered that achieving a complete cytogenetic response had a significant impact on long-term outcome and survival rates.
Breast cancer tumors that become resistant to tamoxifen over-produce a protein called MTA-1, which can be used to predict treatment outcomes and guide therapy selection. Testing for MTA-1 prior to treatment may help devise more aggressive strategies to combat breast cancer.
Researchers found that paroxetine reduces levels of endoxifen, an active metabolite of tamoxifen, in breast cancer patients. This decrease was more pronounced in women with a normal CYP2D6 genotype, suggesting potential implications for tamoxifen treatment outcomes.
Researchers discovered a new metabolite, endoxifen, which is present in higher concentrations than previously thought and varies with genetic composition. This finding suggests that tamoxifen's effectiveness may be influenced by individual differences in metabolism.
A new study found that chemotherapy and radiation together is more effective than sequential treatment in preserving the voice box, with 88% of patients still having their voice after two years. Overall survival rates were similar for all three treatment options.
Researchers analyzed DNA samples from 127 patients with gastrointestinal stromal tumors (GISTs) to determine if a KIT tyrosine kinase mutation was present and its impact on Gleevec response. Patients with favorable lab results had an 84 percent chance of partial remission, while those with unfavorable results did not respond.
New class of drugs targets specific molecules within brain cancer cells, slowing growth and reducing side effects. Three drugs - ZD6474, SB431542, and AEE788 - demonstrate significant promise in treating glioblastoma and other types of brain tumors.
BAY 43-9006 shows promise as a treatment for kidney cancer, with 42% of patients experiencing tumor shrinkage. The compound targets both Raf kinase and VEGFR2, inhibiting tumor growth and angiogenesis.
Researchers found tumor shrinkage and arrest in patients with advanced malignancies treated with SU11248, an oral histone deacetylase inhibitor SAHA, and BAY 43-9006, targeting angiogenesis and cell growth signaling molecules. These preliminary results confirm the promise of these therapeutic approaches.
A phase II trial found that 42% of patients with metastatic kidney cancer experienced at least a 25% reduction in tumor size, with 6 patients experiencing a 50% or greater response. The study's innovative design validated a new approach to phase II trial design.
Researchers at Baylor College of Medicine have identified a novel secretory protein specific to neuroblastoma, which could provide clues to differentiating between aggressive tumors and those that are more likely to respond to treatment. Additionally, scientists have discovered selective inhibitors of key protein kinases implicated in ...
A study by St. Jude Children's Research Hospital found that the anti-cancer drug CCI-779 can prevent abnormal brain growth and reverse seizures in lab mice lacking the Pten gene. The researchers used a mouse model to demonstrate that mTor plays multiple roles in the brain, driving cell growth and signaling pathways.
Researchers will discuss novel targets for controlling cancer growth, such as the circadian rhythm of cells and VEGF, a key player in tumor angiogenesis. The conference also aims to improve radiotherapy effectiveness for head and neck cancers by tailoring therapy to individual tumors.
Researchers at Fox Chase Cancer Center discovered a novel DNA-repair gene mutation that causes resistance to cancer drugs, particularly in colorectal cancer. The defective MED1 enzyme interferes with chemotherapy's effectiveness, making cancers resistant to widely used treatments.
The UCI Cancer Center is one of six institutions nationwide chosen to conduct early-phase clinical trials testing cancer prevention agents. The center will receive over $2.2 million initially, with a focus on assessing the potential of various substances in preventing cancer recurrence.
Researchers demonstrate that removing beta-1 integrin gene prevents breast cancer growth in mice, halting tumor progression and even regressing advanced cancers. However, some tumors spontaneously recur over time, highlighting the need for further investigation into mechanisms of resistance.
Current drinkers who consume at least 30 grams of alcohol daily have an 80% higher risk of breast cancer compared to nondrinkers. Alcohol is associated with a strong increase in hormonally responsive types of breast cancer, including lobular and ER+/PR+ tumors.
The FDNY Tobacco Cessation Program, a free, multi-modal approach, shows a 10-fold increase in quit rates compared to previous studies. At 6 months, 39% of participants were tobacco-free, with the program's success attributed to its combination nicotine replacement therapy and behavior-stress support.
Dr. Yuan Chang discovered human herpesvirus 8 (KSHV) in 1994 and has since studied its biology to understand how it causes cancer. Her work has transformed understanding of the most common malignancy in people infected with HIV.
Gefinitib, a designer drug targeting the epidermal growth factor receptor, has shown efficacy in treating advanced non-small cell lung cancer. In a phase II clinical trial, 43% of patients experienced symptom improvement and 12% showed partial radiographic responses.
Researchers at Johns Hopkins Kimmel Cancer Center have discovered a gene silencer that blocks cancer cells' ability to repair themselves after chemotherapy and radiation. By reducing the production of targeted repair proteins, the silencer enables cancer cells to become susceptible to therapy.
A new model of cancer development suggests that Id1 activation may be crucial for tumor growth, contradicting previous research. The study, which used mice exposed to carcinogens, found that tumors developed faster in mice without the Id1 gene.
A new combination treatment using arsenic trioxide and radiation has shown promising results in treating glioblastoma, a previously incurable form of brain cancer. The study found that exposing glioblastoma cells to radiation within two hours of receiving a dose of arsenic trioxide amplified the effects of radiation treatment on its own.
Researchers found a significant reduction in breast cancer risk among women taking statins and non-statin lipid-lowering drugs. The study analyzed data from over 7,500 older white women and found a 60-70% lower risk of developing breast cancer.
A new study found that adding aprepitant to standard treatment for nausea and vomiting can effectively prevent these symptoms following chemotherapy. The medication reduced nausea and vomiting both on the day of chemotherapy administration and in the days that followed.
A laboratory study found that methylnaltrexone blocked increases in HIV entry and replication when immune cells are exposed to therapeutic doses of morphine. The study suggests that the drug may improve care for patients with AIDS who require pain relief, potentially reducing the risk of severe constipation.
A clinical trial found that taking letrozole after five years of tamoxifen therapy can substantially increase the chance of remaining cancer-free. The study showed a significant reduction in breast cancer recurrence and deaths among women on letrozole compared to those on the placebo.
A clinical trial has found that letrozole significantly improves the long-term outlook for breast cancer survivors, reducing the risk of recurrence by 43%. The study showed that women taking letrozole had a lower risk of disease recurrence and deaths from breast cancer compared to those on the placebo.
A new study shows that letrozole picks up where tamoxifen leaves off in preventing breast cancer recurrence. Women who have been treated for breast cancer and are now cancer-free may need to consider additional treatment options, such as letrozole, based on their individual risk factors.
Researchers developed a molecular test that detects residual cancer cells with high accuracy, outperforming standard cytogenetic analysis. The test predicts disease progression and can be used to stratify patients according to their level of remission, potentially shortening clinical trial duration.
Researchers at Penn aim to understand factors influencing poor prostate cancer outcomes among African-American men, including biological, environmental, and behavioral aspects. The study's findings may help develop better tools for prevention and treatment, ultimately improving clinical outcomes for this underserved population.
A study found racial and ethnic disparities in pain perception, diagnosis, and treatment across various specialties. Disparities were seen in emergency departments, cancer clinics, chronic pain, and disability, with African Americans and Hispanics facing unequal access to pain medication and treatment.
A recent study of early-stage breast cancer patients found that tamoxifen is effective in reducing recurrence and mortality regardless of body mass index. However, obesity was linked to increased risks of second cancers and all-cause mortality.
A new treatment approach uses a Trojan Horse technique to deliver a radioactive isotope into breast cancer cells, slowing tumour growth. The therapy combines EGF with Indium-111, exploiting the natural uptake of EGF by breast cancer cells.
Researchers identified a link between LKB1, an enzyme that reduces blood glucose levels, and AMPK, which inhibits cell growth. This connection could lead to more effective anti-diabetes drugs, such as metformin, also being used to treat cancer. The study found that LKB1 plays a crucial role in preventing tumor growth by activating AMPK.
The European CanCer Organisation warns that the definition of a trial sponsor may lead to the collapse of independent clinical trials, particularly in children's cancers and rare adult cancers. Publicly funded clinical trials will be forced to stop due to financial and administrative burdens.
A new study by ATAC found that Anastrozole enhances disease-free survival and reduces breast cancer recurrence, but increases bone fracture risk. The fracture rate peaks at 18-24 months before stabilizing, suggesting the overall benefit of Anastrozole remains
Researchers have discovered a novel molecular mechanism that explains why certain Hsp90 inhibitors are effective against tumor cells while being non-toxic to normal tissues. This breakthrough has significant implications for the development of targeted cancer therapies and may lead to new treatments for various types of cancer.
Researchers identify key genes involved in cancer development, including BRAF, and develop targeted drugs to combat the disease. A new approach to cancer treatment is being explored by targeting mutated genes, offering new hope for more efficient treatments.
Long-term health consequences of cancer therapy affect nearly all organ systems in pediatric cancer survivors, leading to impaired physical functioning and mental health issues. Women are 40% more likely than men to experience long-term problems.
Patients who traveled farther for cancer treatment had improved overall and progression-free survival rates, suggesting that access to information and resources plays a crucial role in cancer outcomes. The study's findings highlight the importance of considering travel distance as a potential factor in phase II clinical trial results.
Researchers have developed a program to train cancer registrars to track patients' comorbidities, increasing the accuracy of cancer profiles and treatment outcomes. The method is easy for registrars to learn and has shown significant improvements in patient care.
TM has shown promising results in treating Wilson's disease by reducing copper levels, while also inhibiting tumor growth and inflammation in various cancers. The drug's potential to treat inflammatory fibrosis diseases is being explored through ongoing clinical trials.
Researchers at the University of Iowa have discovered a way to improve cancer immunotherapy by directing specific types of white blood cells to kill cancer cells. By using CpG ODN agents, doctors can gear up natural killer cells and granulocytes to work with antibodies to target cancer cells more effectively.
A new combination cancer-killing drug regimen has shown promising results in extending patient survival, with 16% tumor shrinkage and 35% stable disease progression after six months. The orally administered treatment has been well-tolerated and offers a more convenient option for patients compared to traditional IV chemotherapy.
Researchers identify unsuspected gene C/EBP-beta as key mediator of cyclin D1 action in human tumors. The technique combines data from the Global Cancer Map and gene chips to pinpoint gene interactions that lead to cancer.
Researchers found that a paclitaxel combination improved median and long-term survival rates for patients with early-stage SCLC. The treatment also reduced side effects compared to standard chemotherapy.
Consuming phytoestrogens found in plant foods like soy is associated with a reduced risk of endometrial cancer. Imiquimod has been shown to induce apoptosis in skin cancer cells, while an integrin polymorphism may increase cancer progression. The study on breast cancer survivors also found increased numbers of circulating T lymphocytes.
Research suggests that a mutation in a tyrosine kinase receptor gene, when combined with aml1-eto gene mutation, can cause acute myeloid leukemia in mice. This discovery raises the possibility of new treatments targeting these genes to control the disease.
A recent study confirms oxaliplatin's safety in treating advanced colorectal cancer, with low rates of high-grade gastrointestinal side effects. The treatment regimen, combined with fluorouracil and leucovorin, showed improved results in patients who had previously failed first-line chemotherapy.
A Phase III trial found that pemetrexed and cisplatin significantly improved one-year survival rates for mesothelioma patients to 56.5%, compared to 41.9% for those receiving only cisplatin.
CYC202 demonstrates significant cancer cell death, with 54% of patients testing positive for apoptosis following single agent treatment. Seven patients experienced long-lasting tumour stabilisation in Phase I trials, showcasing potential for selective treatment based on genetic profiles.
Researchers at Wake Forest University Baptist Medical Center have found that oxaliplatin can effectively treat human cancers resistant to other platinum-based therapies. The drug works differently than cisplatin and shows promise in combination with radiation therapy for patients with earlier stages of rectal cancer.
Researchers have developed a new generation of targeted cancer therapies using bispecific antibodies that target multiple proteins in cancer cells, increasing radiation sensitivity and specificity. The therapy is expected to improve treatment outcomes for patients with breast and ovarian cancers.
A national study found that 43% of patients reported nausea on the day of treatment, and 73% experienced nausea one or more days later. Delayed nausea is a significant problem, affecting twice as many patients who felt ill in the following days compared to those who felt queasy initially.